Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Asterias Biotherapeutics Inc    AST

ASTERIAS BIOTHERAPEUTICS INC (AST)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Asterias Biotherapeutics : Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2018 | 10:45am CEST

Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the safety and tolerability data generated in the first patient enrolled in the study and recommended continuation of the study and moving to parallel enrollment of the second and third patients in the advanced cancer cohort (Arm A), as planned per the studys protocol. This initial clinical trial, which is being sponsored, managed and funded by Cancer Research UK under a collaboration between Asterias and Cancer Research UK, will examine the safety and tolerability of AST-VAC2 in non-small cell lung cancer (NSCLC) as the studys primary endpoints. Secondary and tertiary endpoints of the study include evaluations of the immunogenicity of AST-VAC2 in NSCLC.

"Based on its review of all available study data after five doses in the first patient, the Safety Review Committees recommendation to continue the trial without modification reaffirms our belief that AST-VAC2 is safe and well-tolerated," commented Dr Edward Wirth, Chief Medical Officer of Asterias Biotherapeutics. The committee concluded that the trial can proceed as planned per protocol - an important step as we continue the clinical development of AST-VAC2."

The Safety Review Committee reviewed all of the accumulated safety data generated to date for the first patient in Arm A (advanced disease), who by the time of the review had received five, weekly doses of 10 million AST-VAC2 cells.

As specified in the AST-VAC2 clinical trial protocol, the Safety Review Committee meets on a dosing-driven basis to review safety and tolerability data from the ongoing trial. The committee is comprised of a group of medical and scientific experts and is responsible for reviewing and evaluating patient safety data in order to safeguard the wellbeing of trial participants.

(c) 2018 Gulf Sports Media All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ASTERIAS BIOTHERAPEUTICS I
07/16ASTERIAS BIOTHERAPEUTICS : Announces New Exclusive License Agreement
AQ
07/13ASTERIAS BIOTHERAPEUTICS : Announces Positive Outcome from Safety Review Committ..
AQ
07/13AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Di..
AQ
07/12ASTERIAS BIOTHERAPEUTICS : soars after key recommendation to continue study of i..
AQ
07/12BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Ther..
AQ
07/12Asterias Biotherapeutics Announces New Exclusive License Agreement with The R..
GL
07/12ASTERIAS BIOTHERAPEUTICS : Announces Positive Outcome from Safety Review Committ..
AQ
07/11ASTERIAS BIOTHERAPEUTICS : Announces Positive Outcome from Safety Review Committ..
AQ
07/04BioTime Awarded Grant from the NIH
AQ
06/28BioTime Licenses GMP Cell Line to Goliver Therapeutics
AQ
More news
News from SeekingAlpha
07/16Asterias' Ischemic Stroke Indication Has The Potential To Add Solid Value To .. 
07/13YOUR DAILY PHARMA SCOOP : ResTORbio Progresses, Roche Closer To Review, AbbVie F.. 
07/12ASTERIAS BIOTHERAPEUTICS' CANCER ASS : What This Means For The Company 
07/12HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (07/12/2018) 
07/12Asterias Bio nabs patent rights to method for improving recovery in stroke pa.. 
Financials ($)
Sales 2018 0,75 M
EBIT 2018 -21,1 M
Net income 2018 -18,6 M
Finance 2018 37,0 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 83,0x
EV / Sales 2019 83,0x
Capitalization 99,0 M
Chart ASTERIAS BIOTHERAPEUTICS I
Duration : Period :
Asterias Biotherapeutics I Technical Analysis Chart | AST | US04624N1072 | 4-Traders
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 8,58 $
Spread / Average Target 377%
EPS Revisions
Managers
NameTitle
Michael H. Mulroy President, Chief Executive Officer & Director
Don Matthew Bailey Non-Executive Chairman
Ryan D. Chavez CFO, Secretary & General Counsel
Edward D. Wirth Chief Medical Officer
Craig Halberstadt Senior VP-Research & Product Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTERIAS BIOTHERAPEUTICS INC-20.00%88
CELLTRION, INC.--.--%31 997
IQVIA HOLDINGS INC9.57%22 131
LONZA GROUP9.72%21 465
INCYTE CORPORATION-25.89%14 878
SEATTLE GENETICS, INC.31.68%11 147